Mereo BioPharma Group plc
MREO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | 73.6% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -2,858.8% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -2,923.2% | – | – |
| EPS Diluted | -0.05 | -0.093 | -0.082 | -0.045 |
| % Growth | 45.9% | -12.8% | -82.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |